Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion

Ductal Carcinoma in Situ Clinical Trial

— TOLERANT  

Official title:

Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion: a Randomized Phase II Biomarker Trial in Subjects at Increased Risk

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06033092
• Other study ID #: UID 3751
• Secondary ID: 2023-503994-39-0
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: May 2024
• Est. completion date: July 31, 2026

Study information

• Verified date: July 2023
• Source: European Institute of Oncology
• Contact: Bernardo Bonanni, MD
• Phone: +39025749022
• Email: bernardo.bonanni[@]ieo.it
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Circulating levels of Sex Hormone Binding Globulin (SHBG) are significantly associated with a decreased risk of breast cancer.

The main aim of this clinical trial is to verify whether Low Dose Tamoxifen (LDT) increases circulating levels of SHBG more than lifestyle intervention (LI) with or without intermittent caloric restriction (ICR) after 6 months in women at increased risk of breast cancer (i.e., healthy participants carriers of a germline pathogenic/likely pathogenetic variant in at least one of the following genes: BRCA1, BRCA2, PALB2, ATM, CHEK2, CDH1, RAD51C or RAD51D, or with > 5% breast cancer risk at 10 years, using the Tyrer Cuzick or the Breast Cancer Surveillance Consortium Risk models or with a recently resected intraepithelial neoplasia of the breast (IEN).

The secondary aims are:

• to verify whether ICR significantly modulates primary and secondary endpoints such as Homeostasis Model Assessment (HOMA) index, immune and inflammatory markers, lipid profile, Adiponectin/Leptin (A/L) ratio, quality of life (QoL), Body mass index (BMI), fat body composition, safety and toxicity;

• to verify whether LDT significantly modulates secondary endpoints, such as HOMA-index, immune and inflammatory markers, lipid profile, A/L ratio, QoL, BMI, fat body composition, safety and toxicity;

• to investigate differences in microbiome composition by arms and the effect of changes in microbiome on QoL taking into account circulating biomarkers, cytokines, immune modulators, and inflammatory proteins in serum;

• to investigate MD (Mammographic Breast Density) changes by LDT vs. LI, with or without ICR. This aim will be performed in a subgroup of participants (not all the participants will undergo mammography due to younger age).

Description:

Italian, multicenter, phase II, biomarker trial. A total of 200 women aged 18-70 years will be randomly assigned (1:1:1:1) to one of the four intervention arms Arm 1: Low dose Tamoxifen (LDT) i.e. 10 mg every other day; Arm 2: Low dose Tamoxifen (LDT) + Intermittent Caloric Restriction (ICR); Arm 3: Lifestyle intervention (LI) using a step counter; Arm 4: Lifestyle intervention (LI) using a step counter + Intermittent Caloric Restriction (ICR).

Participants will be stratified by center and by disease status (high risk vs. previous IEN) and intervention will last six months for all arms.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 200
• Est. completion date: July 31, 2026
• Est. primary completion date: July 31, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Women between 18 and 70 years old;

2. Healthy participants carriers of a germline pathogenic/likely pathogenetic variant in at least one of the following genes BRCA1, BRCA2, PALB2, ATM, CHEK2, CDH1, RAD51C or RAD51D, or

> 5% breast cancer risk at 10 years, using the Tyrer Cuzick or the Breast Cancer Surveillance Consortium Risk models, or

with previous diagnosis of intraepithelial neoplasia (surgery for ADH, LCIS, ER positive DCIS) within the last 3 years;

3. Ability to understand and the willingness to sign a written informed consent document;

4. Eastern Cooperative Oncology Group (ECOG) Performance Status =1;

5a. For high-risk strata: A negative mammogram or any radiological image based on age and center protocol screening within 6 months before baseline visit;

5b. For IEN Strata: A negative mammogram within 12 months before baseline visit;

6. A negative transvaginal ultrasound within 6 months before baseline visit.

Exclusion Criteria:

1. Diagnosis of ER-negative (<10%) DCIS, or history of invasive breast cancer;

2. Previous treatment with SERMs or any other hormonal treatment for breast neoplasms;

3. BMI < 18.5 Kg/m2 and/or Malnutrition Universal Screening Tool (MUST) score =2 and/or any current or past eating disorders;

4. Any diagnosis of invasive neoplasia, except non-melanoma skin cancer, in the previous 5 years;

5. Any tamoxifen contraindications (abnormal liver function, previous ischemic heart disease, endometrial disorder, previous deep venous thrombosis, history of pulmonary embolus, current or suspected glaucoma, retinopathy and cataract);

6. Current use of warfarin or other anticoagulant drugs

7. Bilateral mastectomy;

8. Pregnancy or desire to become pregnant in the subsequent 9 months after treatment cessation;

9. Diabetes or any other clinical condition that at the investigator's discretion contraindicates the proposed intervention.

10. No hormonal contraception is allowed during study intervention. Non-hormonal methods will be advised for women of childbearing potential (WOCBP)

Related Conditions & MeSH terms

• ATM Gene Mutation
• BRCA Mutation
• Breast Carcinoma In Situ
• Carcinoma
• Carcinoma in Situ
• Carcinoma, Ductal
• Carcinoma, Intraductal, Noninfiltrating
• Carcinoma, Lobular
• CDH1 Gene Mutation
• CHEK2 Gene Mutation
• Ductal Carcinoma in Situ
• Lobular Carcinoma in Situ
• PALB2 Gene Mutation
• RAD51C Gene Mutation
• RAD51D Gene Mutation

Intervention

Drug:
• Tamoxifen 10 mg Tablet
One tablet of Tamoxifen 10 mg every other day for 6 months

Other:
• Intermittent caloric restriction
"5:2 diet": 5 days a week at regular energy intake and 2 days/week at 75% energy deficit (diet will be restricted at 500-800 kcal corresponding to a 75% reduction compared to normal size)

Behavioral:
• Step counter Device
Participants will receive personal advice on healthy lifestyle and a step counter

Locations

Country	Name	City	State
Italy	E.O. Galliera	Genoa
Italy	Istituto Europeo di Oncologia	Milan
Italy	Istituto Nazionale Tumori G. Pascale	Napoli
Italy	Istituto Oncologico Veneto	Padova

Sponsors (4)

Lead Sponsor	Collaborator
European Institute of Oncology	Ente Ospedaliero Ospedali Galliera, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Istituto Oncologico Veneto IRCCS

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Post intervention levels of circulating binding globulin	Sex hormone binding globulin level after 6 months of intervention	Through study completion, an average of 6 months